## Introduction

The liver is one of the most essential organs in the human body. When it loses function, it gradually progresses toward failure and may eventually require a liver transplant. Thanks to advancements in transplant surgery and the continuous development of anti-rejection medications, post-operative organ rejection and drug side effects have been significantly reduced. As a result, one-year survival rates after liver transplantation have reached 93%, and five-year survival rates have reached 75%. The following is a brief introduction to liver transplantation:

## I. When is liver transplantation required?

When irreversible, progressive liver disease occurs and no other effective treatment options are available, liver transplantation is the only treatment method capable of extending life.

## II. Indications for liver transplantation

(1) Liver cirrhosis caused by viral hepatitis (B hepatitis, C hepatitis).

(2) Primary hepatic malignant tumors in patients whose liver function makes tumor resection surgery unsuitable (according to literature and the Ministry of Health and Welfare guidelines: a single tumor smaller than 6.5 cm, fewer than three metastatic tumors, with no single tumor diameter exceeding 4.5 cm, and a total diameter not exceeding 8 cm).

(3) Acute liver failure due to fulminant hepatitis or drug-induced liver failure.

(4) Wilson's disease (abnormal copper metabolism).

(5) Congenital biliary atresia (common in children in Taiwan).

(6) Primary biliary cholangitis and primary sclerosing cholangitis:

(1) Primary biliary cholangitis  
(2) Primary sclerosing cholangitis

(7) Other end-stage liver diseases that cannot be treated with conventional therapies.

## III. Contraindications for liver transplantation

(1) Patients with uncontrolled infections.

(2) HIV-positive individuals, but only if the following conditions are met:

(1) CD4 count greater than 200 cells/Î¼l for at least six months.

(2) Adherence to medical advice and stable treatment with antiretroviral therapy, with recent viral load less than 50 copies/ml over the past six months.

(3) No uncontrolled, potentially fatal opportunistic infections or tumors are present.

(4) There remains a future option for antiretroviral therapy.

(3) Patients with untreated tuberculosis.

(4) Patients with malignant tumors (excluding primary liver tumors).

(5) Patients clinically assessed as unable to comply with long-term post-transplant treatment.

(6) Patients with severe cardiovascular or pulmonary dysfunction.

(7) Patients with severe cerebrovascular or peripheral vascular disease, resulting in inability to perform daily activities and who cannot undergo reconstructive surgery.

(8) Patients with immunodeficiency or autoimmune diseases, even after treatment, who have a poor prognosis.

(9) Patients with substance abuse disorders.

(10) Patients with alcohol addiction who have not completed abstinence for more than six months.

<div style="text-align: center;">IV. Pre-transplant evaluation</div>

<div style="text-align: center;"><img src="imgs/img_in_image_box_1118_78_1684_1181.jpg" alt="Image" width="33%" /></div>